Nestlé boosts investment in Aimmune following recent US approval of Palforzia peanut allergy treatment

Aimmune Therapeutics said Wednesday that Nestlé's health science arm will make an additional equity investment in the company of $200 million, bringing its total investment in Aimmune to date to $473 million. The news follows the FDA clearance last week of Aimmune's Palforzia (peanut allergen powder-dnfp), also known as AR101, as the first approved treatment for patients with peanut allergy.

"This additional capital strengthens our financial position as we prepare to launch Palforzia," commented Aimmune CEO Jayson Dallas, adding that it will also "help fund the continued advancement of our pipeline, including conducting clinical trials of [the investigational humanised monoclonal antibody] AIMab7195, which we recently in-licensed from Xencor" for the development of next-generation food allergy treatments. Dallas noted that Nestlé has been an "important equity investor and strategic partner…since we entered into our original collaboration in 2016." 

Greg Behar, chief executive at Nestlé Health Science, remarked "we are impressed with the progress Aimmune has made as it prepares to launch Palforzia," adding "our further investment in Aimmune is intended to help assure [the peanut allergy treatment's] longer-term commercial success."

Meanwhile, Piper Sandler analyst Christopher Raymond suggested that "with this additional investment, we think the prospect of an outright take out [of Aimmune] by Nestlé, or anyone else for that matter, has to be factored in more than before."

After the completion of the latest transaction, expected on February 7, Nestlé's total investments in Aimmune will correspond to ownership of 19.9% of Aimmune's outstanding common stock and voting power. 

To read more Top Story articles, click here.